Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sleep Apnea, Central | 14 | 2026 | 16 | 4.340 |
Why?
|
| Heart Failure | 18 | 2023 | 253 | 3.220 |
Why?
|
| Electric Stimulation Therapy | 9 | 2026 | 58 | 2.460 |
Why?
|
| Phrenic Nerve | 9 | 2026 | 24 | 2.160 |
Why?
|
| Sleep Apnea Syndromes | 4 | 2023 | 32 | 1.490 |
Why?
|
| Sleep Apnea, Obstructive | 5 | 2025 | 43 | 1.260 |
Why?
|
| Quality of Life | 5 | 2026 | 521 | 0.930 |
Why?
|
| Atrial Fibrillation | 2 | 2026 | 404 | 0.720 |
Why?
|
| Polysomnography | 6 | 2026 | 48 | 0.630 |
Why?
|
| Monitoring, Ambulatory | 3 | 2009 | 26 | 0.620 |
Why?
|
| Diaphragm | 2 | 2020 | 16 | 0.590 |
Why?
|
| Treatment Outcome | 11 | 2026 | 2426 | 0.470 |
Why?
|
| Respiratory Mechanics | 1 | 2014 | 17 | 0.420 |
Why?
|
| Defibrillators, Implantable | 3 | 2009 | 46 | 0.400 |
Why?
|
| Humans | 27 | 2026 | 28870 | 0.390 |
Why?
|
| Cardiography, Impedance | 3 | 2011 | 7 | 0.360 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 381 | 0.350 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2011 | 18 | 0.340 |
Why?
|
| Aged | 11 | 2026 | 5598 | 0.300 |
Why?
|
| Oxygen | 3 | 2020 | 237 | 0.290 |
Why?
|
| Plasma Volume | 1 | 2008 | 6 | 0.280 |
Why?
|
| Monitoring, Physiologic | 1 | 2008 | 58 | 0.280 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2007 | 5 | 0.260 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2006 | 8 | 0.240 |
Why?
|
| Tetrazoles | 1 | 2006 | 9 | 0.240 |
Why?
|
| Middle Aged | 9 | 2026 | 7415 | 0.240 |
Why?
|
| Benzimidazoles | 1 | 2006 | 32 | 0.240 |
Why?
|
| Male | 12 | 2026 | 13931 | 0.230 |
Why?
|
| Patient Selection | 1 | 2025 | 150 | 0.230 |
Why?
|
| Sleep | 2 | 2023 | 112 | 0.220 |
Why?
|
| Female | 13 | 2026 | 15631 | 0.220 |
Why?
|
| Comorbidity | 3 | 2025 | 261 | 0.190 |
Why?
|
| Continuous Positive Airway Pressure | 2 | 2020 | 13 | 0.190 |
Why?
|
| Risk Factors | 5 | 2025 | 2126 | 0.160 |
Why?
|
| Coronary Artery Disease | 1 | 2023 | 220 | 0.160 |
Why?
|
| Catheterization, Peripheral | 1 | 2020 | 24 | 0.160 |
Why?
|
| Retrospective Studies | 2 | 2026 | 2635 | 0.160 |
Why?
|
| Circadian Rhythm | 1 | 2020 | 76 | 0.160 |
Why?
|
| Hypertension | 1 | 2023 | 309 | 0.160 |
Why?
|
| Hypoxia | 1 | 2020 | 90 | 0.160 |
Why?
|
| Stroke Volume | 1 | 2020 | 124 | 0.150 |
Why?
|
| Sleep, REM | 1 | 2019 | 21 | 0.150 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 115 | 0.140 |
Why?
|
| Prospective Studies | 5 | 2022 | 1280 | 0.130 |
Why?
|
| Implantable Neurostimulators | 1 | 2017 | 2 | 0.130 |
Why?
|
| Positive-Pressure Respiration | 1 | 2017 | 14 | 0.130 |
Why?
|
| Masks | 1 | 2017 | 11 | 0.130 |
Why?
|
| Multicenter Studies as Topic | 1 | 2017 | 48 | 0.130 |
Why?
|
| Carbon Dioxide | 1 | 2017 | 94 | 0.120 |
Why?
|
| Global Health | 1 | 2015 | 54 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 403 | 0.110 |
Why?
|
| Hemodynamics | 2 | 2008 | 221 | 0.110 |
Why?
|
| Equipment Design | 1 | 2014 | 218 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 1032 | 0.100 |
Why?
|
| Patient Care | 1 | 2011 | 13 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2011 | 98 | 0.090 |
Why?
|
| Physician-Patient Relations | 1 | 2011 | 116 | 0.080 |
Why?
|
| Blood Volume | 1 | 2010 | 8 | 0.080 |
Why?
|
| Lung | 1 | 2013 | 382 | 0.080 |
Why?
|
| Warfarin | 1 | 2010 | 94 | 0.080 |
Why?
|
| Sex Factors | 1 | 2011 | 467 | 0.080 |
Why?
|
| Adult | 5 | 2025 | 8026 | 0.070 |
Why?
|
| Time Factors | 3 | 2020 | 1613 | 0.070 |
Why?
|
| Prevalence | 2 | 2025 | 518 | 0.070 |
Why?
|
| Telemetry | 1 | 2008 | 8 | 0.070 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2008 | 3 | 0.070 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2008 | 11 | 0.070 |
Why?
|
| Echocardiography | 1 | 2008 | 110 | 0.070 |
Why?
|
| Anticoagulants | 1 | 2010 | 297 | 0.070 |
Why?
|
| Heart-Assist Devices | 1 | 2008 | 33 | 0.070 |
Why?
|
| Hospitalization | 1 | 2009 | 201 | 0.070 |
Why?
|
| Decision Trees | 1 | 2007 | 8 | 0.070 |
Why?
|
| Body Weight | 1 | 2008 | 250 | 0.070 |
Why?
|
| Heart Rate | 1 | 2008 | 382 | 0.060 |
Why?
|
| Heart Failure, Systolic | 1 | 2006 | 3 | 0.060 |
Why?
|
| Death, Sudden | 1 | 2006 | 15 | 0.060 |
Why?
|
| Hyperkalemia | 1 | 2006 | 8 | 0.060 |
Why?
|
| Biphenyl Compounds | 1 | 2006 | 22 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2006 | 61 | 0.060 |
Why?
|
| Etiocholanolone | 1 | 2003 | 1 | 0.050 |
Why?
|
| Dobutamine | 1 | 2003 | 7 | 0.050 |
Why?
|
| Cardiotonic Agents | 1 | 2003 | 28 | 0.050 |
Why?
|
| Apolipoproteins C | 1 | 2003 | 4 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 465 | 0.050 |
Why?
|
| Apolipoproteins B | 1 | 2003 | 18 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2003 | 64 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2003 | 99 | 0.050 |
Why?
|
| Pandemics | 1 | 2023 | 199 | 0.040 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2020 | 25 | 0.040 |
Why?
|
| Cheyne-Stokes Respiration | 1 | 2020 | 1 | 0.040 |
Why?
|
| Respiration | 1 | 2020 | 45 | 0.040 |
Why?
|
| Patient Safety | 1 | 2019 | 39 | 0.040 |
Why?
|
| Patients | 1 | 2019 | 17 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2010 | 897 | 0.030 |
Why?
|
| Biomarkers | 1 | 2020 | 777 | 0.030 |
Why?
|
| Obesity | 1 | 2003 | 701 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2010 | 2065 | 0.030 |
Why?
|
| Arousal | 1 | 2011 | 38 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 222 | 0.020 |
Why?
|
| International Normalized Ratio | 1 | 2010 | 27 | 0.020 |
Why?
|
| Disease Progression | 1 | 2011 | 477 | 0.020 |
Why?
|
| Registries | 1 | 2011 | 397 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 631 | 0.020 |
Why?
|
| Prognosis | 1 | 2011 | 811 | 0.020 |
Why?
|
| Electric Impedance | 1 | 2009 | 31 | 0.020 |
Why?
|
| Acute Disease | 1 | 2009 | 155 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 612 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 429 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2010 | 463 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 1000 | 0.020 |
Why?
|
| Apolipoprotein C-III | 1 | 2003 | 12 | 0.010 |
Why?
|
| Dogs | 1 | 2003 | 510 | 0.010 |
Why?
|
| Protein Binding | 1 | 2003 | 667 | 0.010 |
Why?
|
| Adolescent | 1 | 2003 | 3194 | 0.010 |
Why?
|
| Animals | 1 | 2003 | 10699 | 0.000 |
Why?
|